Niki BioSolutions, Inc.

NASDAQ: NIKI · Healthcare · Biotechnology

PublicHQ Princeton, NJCIK 0001734005Reports USD

#944 of 1,413 Healthcare companies by revenuebottom-quartile growth

EA Score

——

FH 64DQ —GM —SS —

v0.1 · 30/100 weight · pillars only

↑ balance-sheet leverage, return on assets · ↓ listing tenure, disclosure history

Methodology →

Revenue TTM

$431.4k

Rev growth YoY (TTM)

needs 8 qtrs

Net income (FY)

-$1.4M

Employees

—

Market cap

—

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$431.4k$431.4k2023

Net income-$1.4M-$1.4M2025

Total assets$18.7M$18.7M2025

Liabilities$4.9M$4.9M2025

Equity$23.1M$23.1M2025

Revenue trend

FY2023 – FY2023 · USD

$1.5M

FY23

$1.3M

FY23

$431.4k

FY23

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Niki BioSolutions, Inc. booked $431.4k in FY2023 revenue, contracting 67% year over year — slower than 86% of Healthcare companies we track, at a -316.0% net margin.

Key facts

CEO—

SectorHealthcare

IndustryBiotechnology

HeadquartersPrinceton, NJ

ExchangeNASDAQ: NIKI

Employees—

IPO date2026-07-20

Latest filings

No filings loaded.

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.